Connect with us

Micro Cap Insider

Probility Media Corp (OTCMKTS: PBYA) Major Runner As NACB & One Exam Prep Gain Traction

Published

on

Probility Media Corp (OTCMKTS: PBYA) is making a powerful move up the charts in recent days on an all-out blue sky breakout surpassing a penny and posting over $6 million in dollar volume on Monday alone. The stock is getting noticed by some pretty heavy hitter penny stock players. PBYA is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. PBYA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – currently PBYA is on a blue-sky breakout!  

PBYA has a number of subsidiaries making big moves; NACB, a subsidiary of ProBility Media Corp., conducts over 400 safety programs each year all over the world.  A partial list of customers includes companies such as Alcoa, Dow Chemical, Exxon Mobil, Fluor, General Electric, IBM, Kaiser Aluminum, Lockheed Martin, Los Alamos National Labs, Shell Oil, U.S. Navy, U.S Steel and many more. With training facilities located in Central Florida, Cincinnati, OH and Southeast Texas, customers can receive hands-on crane operator training at these locations. Several days ago, the NACB initiated new training programs for Tesla (Nasdaq: TSLA), Marathon (NYSE: MRO) and BAE Systems (OTC: BASEY). Another subsidiary of PBYA is One Exam Prep, offering over 500 online courses and test preparation for contractors in over 15 states.  In addition, One Exam has published over 300 test preparation books that have become some of the most widely sold materials in multiple trade industries including that of electrical work. One Exam Prep is also a licensed and accredited continuing education provider in the state of Florida. On June 30 PBYA reported online classes have seen a fivefold increase since the start of Covid-19. One Exam Prep has quickly become one of the largest test prep companies in Florida.   

Probility Media Corp (OTCMKTS: PBYA) is an industrial education and training technology company headquartered in Coconut Creek, Florida, offering education online and in person programs including training in a variety of vocational industries. ProBility is executing a disruptive strategy of defragmenting the education and training market place by offering high quality training courses and materials to prepare the workforce for excellence. ProBility services customers from the individual to the small business to the enterprise level corporation. The Company recently reported it plans to become current with its filing obligations pursuant to Securities Exchange Act Rule 15c-211 and OTC Markets Group Inc. Reporting Guidelines prior to Sept. 28, 2021. The Company specifically plans to file with the OTC Markets its Annual Disclosure Report for the years ended 2020 and 2021 as well as any Quarterly Disclosure Reports as they become due. The Company’s fiscal year end is May 31.  

PBYA has a number of subsidiaries making big moves; NACB, a subsidiary of ProBility Media Corp., conducts over 400 safety programs each year all over the world.  A partial list of customers includes companies such as Alcoa, Dow Chemical, Exxon Mobil, Fluor, General Electric, IBM, Kaiser Aluminum, Lockheed Martin, Los Alamos National Labs, Shell Oil, U.S. Navy, U.S Steel and many more. With training facilities located in Central Florida, Cincinnati, OH and Southeast Texas, customers can receive hands-on crane operator training at these locations.   NACB has also published award winning courses in safety, rigging and crane operations. NACB holds a federal accreditation under 29CFR part 1919, Cal/OSHA accreditation under Title 8, and is recognized by several state entities as being qualified to conduct lift equipment inspection / certification and / or operator training / certification.  In 1996 NACB partnered with NCCER to facilitate the development of its first mobile crane operator training series.   Today NACB offers NCCER, ANSI Accredited Certifications for its crane, rigging and signal person certifications as well as a host of NACB Certifications, Authorizations and Qualifications.    

Several days ago the NACB initiated new training programs for Tesla (Nasdaq: TSLA), Marathon (NYSE: MRO) and BAE Systems (OTC: BASEY). These programs consists of onsite training for crane operators, inspectors, rigging personnel and signal personnel and lift equipment trainers within these organizations. In addition, these engagements are long term training arrangements that are expected be replicated throughout their corporate footprint. 

With the loosening of restrictions that resulted from Covid-19, many corporations are scrambling to become compliant with OSHA safety standards, crane inspections and crane operator training and recertification. NACB has recently added additional world class trainers in anticipation of the urgency by companies around the world requiring these safety protocols.  

To Find out the inside Scoop on PBYA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

PBYA

Another subsidiary of PBYA is One Exam Prep, offering over 500 online courses and test preparation for contractors in over 15 states.  In addition, One Exam has published over 300 test preparation books that have become some of the most widely sold materials in multiple trade industries including that of electrical work. One Exam Prep is also a licensed and accredited continuing education provider in the state of Florida. For more information on One Exam Prep, visit www.1examprep.com  

One Exam Prep has taught over 50,000 students in multiple contractor specialties. It has also provided standards, testing and training materials for electrical supply companies such as Wesco (NYSE: WCC), Platt Electric,  a subsidiary of Rexel S.A (RXL.PA), Consolidated Electrical Distributors (CED), City Electric Supply, Graybar and hundreds of other smaller suppliers. In the coming months, One Exam will continue to open new markets for contractor test preparation and continue on its path to reach its goal of being the first nationwide company to offer vocational test preparation for most skilled trades. 

On June 30 PBYA reported online classes have seen a fivefold increase since the start of Covid-19. One Exam Prep has quickly become one of the largest test prep companies in Florida.  By moving to an online only format, One Exam has expanded its classes into more than 15 other states. At the outset of Covid-19, management upgraded its online streaming capabilities becoming one of the first in the industry to offer full programs online.  One Exam also began to offer tutoring services as a form of added services to its students.  Tutoring quickly became one of the most popular services offered as more students wanted individualized attention.  The Company expects tutoring to continue to grow as the landscape continues to evolve into online learning for vocational test preparation. 

We have a Monster Pick Coming. Subscribe Right Now!

Probility Media is making a powerful move up the charts in recent days on an all-out blue sky breakout surpassing a penny and posting over $6 million in dollar volume on Monday alone. The stock is getting noticed by some pretty heavy hitter penny stock players. PBYA is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. PBYA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – currently PBYA is on a blue-sky breakout!  PBYA has a number of subsidiaries making big moves; NACB, a subsidiary of ProBility Media Corp., conducts over 400 safety programs each year all over the world.  A partial list of customers includes companies such as Alcoa, Dow Chemical, Exxon Mobil, Fluor, General Electric, IBM, Kaiser Aluminum, Lockheed Martin, Los Alamos National Labs, Shell Oil, U.S. Navy, U.S Steel and many more. With training facilities located in Central Florida, Cincinnati, OH and Southeast Texas, customers can receive hands-on crane operator training at these locations. Several days ago, the NACB initiated new training programs for Tesla (Nasdaq: TSLA), Marathon (NYSE: MRO) and BAE Systems (OTC: BASEY). Another subsidiary of PBYA is One Exam Prep, offering over 500 online courses and test preparation for contractors in over 15 states.  In addition, One Exam has published over 300 test preparation books that have become some of the most widely sold materials in multiple trade industries including that of electrical work. One Exam Prep is also a licensed and accredited continuing education provider in the state of Florida. On June 30 PBYA reported online classes have seen a fivefold increase since the start of Covid-19. One Exam Prep has quickly become one of the largest test prep companies in Florida. We will be updating on PBYA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PBYA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PBYA either long or short and we have not been compensated for this article.

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

on

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.